Heterocyclic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor
申请人:Drescher Karla
公开号:US20080045493A1
公开(公告)日:2008-02-21
The invention relates to compounds of the formula (I)
wherein n is 0, 1 or 2;
G is CH
2
or CHR
3
;
R
1
is H, C
1
-C
6
-alkyl, C
1
-C
6
-alkyl substituted by C
3
-C
6
-cycloalkyl, C
1
-C
6
-hydroxyalkyl, fluorinated C
1
-C
6
-alkyl, C
3
-C
6
-cycloalkyl, fluorinated C
3
-C
6
-cycloalkyl, C
3
-C
6
-alkenyl, fluorinated C
3
-C
6
-alkenyl, formyl, acetyl or propionyl;
R
2
, R
3
and R
4
are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl;
A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one or more substituents selected from halogen, methyl, methoxy and CF
3
;
E is NR
5
or CH
2
, wherein R
5
is H or C
1
-C
3
-alkyl;
Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR
8
, where R
8
is H, C
1
-C
4
-alkyl, fluorinated C
1
-C
4
-alkyl, C
1
-C
4
-alkylcarbonyl or fluorinated C
1
-C
4
-alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R
a
, wherein the variable R
a
has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
本发明涉及式(I)的化合物,其中n为0、1或2;G为CH2或CHR3;R1为H、C1-C6烷基、C1-C6烷基取代的C3-C6环烷基、C1-C6羟基烷基、氟代C1-C6烷基、C3-C6环烷基、氟代C3-C6环烷基、C3-C6烯基、氟代C3-C6烯基、甲酰基、乙酰基或丙酰基;R2、R3和R4独立地为H、甲基、氟甲基、二氟甲基或三氟甲基;A为苯基、吡啶基、嘧啶基、吡嗪基、吡啶嗪基或噻吩基,可以被一个或多个卤素、甲基、甲氧基和CF3等取代基所取代;E为NR5或CH2,其中R5为H或C1-C3烷基;Ar为从苯基、一个5-或6-成员的杂环芳基基团中选择的循环基团,该杂环芳基基团的环成员包括1、2或3个从N、O和S选择的杂原子和与饱和或不饱和的5-或6-成员碳环或杂环芳基团融合的苯基环,其中所述杂环芳基团包括1、2或3个从N、O和S选择的杂原子和/或1、2或3个从NR8选择的含杂原子基团,其中R8为H、C1-C4烷基、氟代C1-C4烷基、C1-C4烷基羰基或氟代C1-C4烷基羰基,且所述循环基团Ar可以携带1、2或3个取代基Ra,其中变量Ra的含义如权利要求和说明书中所给出;以及其生理耐受的酸加合盐。本发明还涉及使用式I的化合物或其药学上可接受的盐制备用于治疗易于用多巴胺D3受体配体治疗的医疗疾病的药物组合物的用途。